CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:CYTR
- CUSIP: N/A
- Web: www.cytrx.com
- Market Cap: $111 million
- Outstanding Shares: 152,054,000
- 50 Day Moving Avg: $0.52
- 200 Day Moving Avg: $0.46
- 52 Week Range: $0.36 - $3.28
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.78
- P/E Growth: 0.0000
- Annual Revenue: $200,000.00
- Price / Sales: 555.00
- Book Value: $0.12 per share
- Price / Book: 6.08
- EBIDTA: ($49,290,000.00)
- Return on Equity: -213.82%
- Return on Assets: -99.93%
- Debt-to-Equity Ratio: 0.86%
- Current Ratio: 3.06%
- Quick Ratio: 3.06%
- Average Volume: 4.84 million shs.
- Beta: 1.34
- Short Ratio: 7.79
Frequently Asked Questions for CytRx (NASDAQ:CYTR)
What is CytRx's stock symbol?
CytRx trades on the NASDAQ under the ticker symbol "CYTR."
How were CytRx's earnings last quarter?
CytRx Co. (NASDAQ:CYTR) released its earnings results on Wednesday, May, 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. View CytRx's Earnings History.
Where is CytRx's stock going? Where will CytRx's stock price be in 2017?
4 brokers have issued twelve-month price objectives for CytRx's stock. Their predictions range from $0.75 to $4.00. On average, they expect CytRx's stock price to reach $2.13 in the next twelve months. View Analyst Ratings for CytRx.
Are investors shorting CytRx?
CytRx saw a decrease in short interest in May. As of May 15th, there was short interest totalling 10,653,099 shares, a decrease of 51.6% from the April 28th total of 22,015,582 shares. Based on an average daily trading volume, of 3,397,304 shares, the short-interest ratio is presently 3.1 days. Approximately 9.5% of the shares of the company are sold short.
Who are some of CytRx's key competitors?
Some companies that are related to CytRx include Ardelyx (ARDX), Chimerix (CMRX), Corium International (CORI), Codexis (CDXS), Cascadian Therapeutics (CASC), Immune Design Corp (IMDZ), Cempra (CEMP), Fortress Biotech (FBIO), Stemline Therapeutics (STML), Osiris Therapeutics (OSIR), Enzymotec Ltd (ENZY), Madrigal Pharmaceuticals (MDGL), Pieris Pharmaceuticals (PIRS), Arbutus Biopharma Corp (ABUS), VBI Vaccines, Inc. - (VBIV), Peregrine Pharmaceuticals (PPHM), Genocea Biosciences (GNCA) and RedHill Biopharma Ltd - (RDHL).
Who owns CytRx stock?
CytRx's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
SABBY MANAGEMENT, LLC
(8.07%), Vanguard Group Inc. (2.67%), Sabby Management LLC (0.65%), Geode Capital Management LLC (0.63%), Renaissance Technologies LLC (0.51%) and Morgan Stanley (0.20%). View Institutional Ownership Trends for CytRx.
Who sold CytRx stock? Who is selling CytRx stock?
Who bought CytRx stock? Who is buying CytRx stock?
CytRx's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., SG Americas Securities LLC and Geode Capital Management LLC. View Insider Buying and Selling for CytRx.
How do I buy CytRx stock?
Shares of CytRx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CytRx stock cost?
One share of CytRx stock can currently be purchased for approximately $0.73.
Earnings History for CytRx (NASDAQ:CYTR)Earnings History by Quarter for CytRx (NASDAQ:CYTR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/10/2015||Q4 2014||($0.27)||($0.24)||$0.10 million||View||N/A|
Earnings Estimates for CytRx (NASDAQ:CYTR)
Current Year EPS Consensus Estimate: $-0.50 EPS
Next Year EPS Consensus Estimate: $-0.41 EPS
Dividend History for CytRx (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CytRx (NASDAQ:CYTR)
Insider Ownership Percentage: 12.40%Insider Trades by Quarter for CytRx (NASDAQ:CYTR)
Institutional Ownership Percentage: 20.19%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/3/2013||Scott Bradford Patterson||major shareholder||Buy||284,979||$2.44||$695,348.76|| |
|11/7/2013||Scott Bradford Patterson||Major Shareholder||Buy||50,000||$2.06||$103,000.00|| |
|4/1/2013||Scott Bradford Patterson||Major Shareholder||Buy||4,083||$2.70||$11,024.10|| |
|3/20/2013||Scott Bradford Patterson||Major Shareholder||Buy||3,980||$2.61||$10,387.80|| |
|3/13/2013||Scott Bradford Patterson||Major Shareholder||Buy||55,360||$2.67||$147,811.20|| |
|10/22/2012||Scott Bradford Patterson||Major Shareholder||Buy||180,000||$2.51||$451,800.00|| |
|10/18/2012||Scott Bradford Patterson||Major Shareholder||Buy||1,200,000||$2.50||$3,000,000.00|| |
Headline Trends for CytRx (NASDAQ:CYTR)
Latest Headlines for CytRx (NASDAQ:CYTR)
|Most Notable Abstracts Released Ahead Of ASCO 2017 | Benzinga - Benzinga|
www.benzinga.com - May 19 at 4:29 PM
|The Most Notable Abstracts Released Ahead Of ASCO 2017|
finance.yahoo.com - May 19 at 4:29 PM
|Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx|
finance.yahoo.com - May 19 at 8:22 AM
|B. Riley Financial (RILY) Announces $67M Acquisition of Wunderlich Securities|
www.streetinsider.com - May 18 at 10:45 AM
|CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting|
finance.yahoo.com - May 17 at 9:45 PM
|CytRx Co. (CYTR) Posts Earnings Results|
www.americanbankingnews.com - May 11 at 6:54 PM
|CytRx Co. (CYTR) Sees Large Growth in Short Interest|
www.americanbankingnews.com - May 11 at 7:20 AM
|CytRx Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 10 at 4:50 PM
|CytRx reports 1Q loss|
finance.yahoo.com - May 10 at 4:50 PM
|Fake news infiltrates financial markets|
www.ft.com - May 5 at 2:51 AM
|CytRx (CYTR) Announces Offering of Common Stock|
www.streetinsider.com - April 29 at 10:18 PM
|CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock - PR Newswire (press release)|
www.prnewswire.com - April 29 at 5:17 PM
|CytRx (CYTR) Prices 30M Common Stock Offering at $0.50/Share|
www.streetinsider.com - April 29 at 10:28 AM
|BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Starbucks, Time Inc ... - Nasdaq|
www.nasdaq.com - April 28 at 10:42 PM
|CytRx Corporation Announces Proposed Public Offering of Common Stock - PR Newswire (press release)|
www.prnewswire.com - April 28 at 3:13 AM
|CytRx (CYTR) Receiving Somewhat Positive News Coverage, Study Finds|
www.americanbankingnews.com - April 27 at 10:48 PM
|CytRx Corporation Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - April 27 at 10:12 PM
|Penny Stocks to Watch for May 2017|
finance.yahoo.com - April 27 at 5:10 PM
|CytRx Co. (CYTR) Earns "Buy" Rating from HC Wainwright|
www.americanbankingnews.com - April 26 at 9:02 PM
|Somewhat Favorable News Coverage Somewhat Likely to Affect CytRx (CYTR) Share Price|
www.americanbankingnews.com - April 24 at 6:34 PM
|CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)|
finance.yahoo.com - April 21 at 12:23 PM
|CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up|
finance.yahoo.com - April 20 at 9:48 PM
|CytRx (CYTR) Receiving Favorable News Coverage, Report Finds|
www.americanbankingnews.com - April 20 at 8:59 PM
|Blog Coverage CytRx Announces FDA's Approval for New Drug Application|
finance.yahoo.com - April 20 at 4:47 PM
|ETFs with exposure to CytRx Corp. : April 20, 2017|
finance.yahoo.com - April 20 at 4:47 PM
|BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, IBM, Textron ... - Nasdaq|
www.nasdaq.com - April 19 at 9:39 PM
|IBM sends S&P 500, Dow lower; Nasdaq advances|
www.streetinsider.com - April 19 at 4:37 PM
|Integris Software Launches and Unveils Data Privacy Platform for Global Enterprises|
www.streetinsider.com - April 19 at 12:34 PM
|CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas|
finance.yahoo.com - April 19 at 12:34 PM
|For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug ... - TheStreet.com|
www.thestreet.com - April 13 at 4:39 PM
|Somewhat Favorable News Coverage Very Unlikely to Effect CytRx (CYTR) Share Price|
www.americanbankingnews.com - April 13 at 3:49 PM
|ETFs with exposure to CytRx Corp. : April 7, 2017|
finance.yahoo.com - April 7 at 4:37 PM
|CytRx Co. (CYTR) Stock Rating Reaffirmed by Aegis|
www.americanbankingnews.com - March 23 at 8:53 AM
|CYTRX CORP Financials|
finance.yahoo.com - March 21 at 4:55 PM
|CytRx Reports 2016 Financial Results|
finance.yahoo.com - March 15 at 5:03 PM
|CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition|
biz.yahoo.com - March 15 at 5:03 PM
|CytRx to Present at the 29th Annual ROTH Conference|
finance.yahoo.com - March 7 at 12:05 PM
|CYTRX CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf|
biz.yahoo.com - February 24 at 10:10 PM
|CytRx to Present at the 19th Annual BIO CEO & Investor Conference|
finance.yahoo.com - February 6 at 4:41 PM
|CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - January 30 at 9:52 AM
|BRIEF-Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin|
www.reuters.com - January 4 at 5:42 PM
|CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment …|
finance.yahoo.com - January 4 at 5:42 PM
|Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock? - Nasdaq|
www.nasdaq.com - December 30 at 10:02 PM
|Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?|
finance.yahoo.com - December 30 at 5:01 PM
CytRx (CYTR) Chart for Friday, May, 26, 2017